Augustus 2023: Die vaste dosis kombinasie van niraparib en abirateroon asetaat (Akeega, Janssen Biotech, Inc.), saam met prednisoon, is goedgekeur deur die Food and Drug Administration vir volwasse pasiënte met kastrasie-weerstand.
August 2022: Darolutamide (Nubeqa, Bayer HealthCare Pharmaceuticals Inc.) tablets combined with docetaxel were approved by the Food and Drug Administration for adult patients with metastatic hormone-sensitive prostate cancer (mHS..
April 2022: Die Food and Drug Administration het Pluvicto (lutetium Lu 177 vipivotide tetraxetan, Advanced Accelerator Applications USA, Inc., 'n Novartis-maatskappy) goedgekeur vir die behandeling van volwasse pasiënte met prostaat-spesifieke mem.
Maart 2022: HIFU (High Intensity Focused Ultrasound) is 'n toonaangewende terapie wat gefokusde, hoë-energie ultraklankgolwe gebruik om kankeragtige dele van die prostaatklier te verhit en dood te maak. Die teikenweefsel word verhit tot 880 tot 980 grade..
August 2021: The first oral gonadotropin-releasing hormone (GnRH) receptor antagonist, relugolix (ORGOVYX, Myovant Sciences, Inc.), was approved by the Food and Drug Administration on December 18, 2020, for adult patients with met..